secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001420720-25-000024
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio Q3 FY2025 net loss widens to $4.9M; pipeline progress with IBIO-600, Activin E
--------------------------------------------------------------------------------

- Net loss from continuing ops $4.9M ($0.49/share) vs $2.6M ($0.71/share) in Q3 FY2024.
- R&D expenses doubled to $1.9M on advancing IBIO-600 and Activin E programs.
- Cash $5.2M at March 31; after $6.2M warrant inducement in April, cash ~$10.5M as of May 1.
- In-licensed first-in-class Activin E antibody from AstralBio; reported NHP data for IBIO-600 showing dose-dependent muscle growth.
- Trading began on Nasdaq under IBIO; on track for IBIO-600 regulatory submission in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000024/0001420720-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000024/ibio-20250502x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer